Loading stock data…
Emergent BioSolutions Inc. (EBS)
$6.00-0.21 (-3.38%)
Market ClosedLast close Sep 8
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Emergent BioSolutions Inc. in the Healthcare sector is trading at $6.00 with a market capitalization of $409M. Wall Street consensus targets $11.00 (2 analysts), implying a +83.3% move over the next 12 months. The stock is currently near its 52-week low of $4.36, remaining 33.4% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +83.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $226.80M↑ | $149.70M↑ | $143.80M↓ | $222.00M↑ | $130.30M |
| Gross Profit | $129.70M↑ | $77.70M↑ | $58.90M↓ | $136.10M↑ | $63.40M |
| Operating Income | $66.20M↑ | $10.50M↑ | -$15.70M↓ | $76.50M↑ | $1.60M |
| Net Income | -$180.20M↓ | $6.80M↑ | -$54.60M↓ | $51.20M↑ | -$12.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commerc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$409.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.64%
Volume
Today's trading volume
702,796
Recent News
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
MCM deliveries surge but naloxone competition forces restructuring and guidance cuts.
Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows?
Shares of Trade Desk, Papa John’s International, Emergent Biosolutions declined after the companies posted disappointing Q2 results last week.
Emergent Biosolutions Q2 Earnings Call Highlights
Emergent Biosolutions (NYSE:EBS) reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and
Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary
Moby summary of Emergent BioSolutions Inc.'s Q2 2026 earnings call
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in. TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox […]